For nearly two decades, reverse payments have been the perennial focus in the pharmaceutical industry and among antitrust professionals. But while courts continue to grapple with the implications of the Supreme Court’s decision in FTC v. Actavis, Inc., 570 U.S. 136 (2013), more attention is being brought to pharmaceutical companies’ lifecycle management strategies.

Read this chapter in Shearman & Sterling’s 2019 Antitrust Annual Report, “Moving Past Actavis with Evolving Lifecycle Management Strategies”